US 12,673,092 B2Granted

Asparaginase-based cancer therapy

AssigneeKyon Biotech AG

InventorsSlobodan Tepic, Goran Cvetkovic

Life of this patent

Estimating the term…

Abstract

The present invention relates to an improved preparation and delivery of asparaginase for use in medicine, e.g. in human and veterinary medicine.

Claims7

Dependent claims

A method for the treatment of leukemia or lymphoma comprising administering a therapeutically effective amount of monomeric asparaginase in urea to a subject in need thereof, wherein the monomeric asparaginase is administered by intravenous infusion.

Dependencies are inferred from the claim text.

Facts

Application: 17/616,547Filed 29 May 2020
Priority: EP 191780624 Jun 2019
Published: US 2022/0249629 A111 Aug 2022
Granted: 7 Jul 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 38/50
Hydrolases: acting on carbon-nitrogen bonds, other than peptide bonds , e.g. asparaginase
A61K 31/17
Amides, e.g. hydroxamic acids: having the group >N—C—N< or >N—C—N<, e.g. urea, thiourea, carmustine
A61P 35/00
Antineoplastic agents
A61P 35/02
Antineoplastic agents: specific for leukemia

Family

US 2022/0249629 A1Pre-grant publication · published 11 Aug 2022
US 12,673,092 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results